viewOpen Orphan PLC

Open Orphan hVIVO arm lands three new contracts

"We are now continuing to sign additional new virology services contracts with third party customers,” said Open Orphan chairman Cathal Friel

Open Orphan PLC -

Open Orphan PLC (LON:ORPH) said its hVIVO lab services operation has signed three new contracts, adding to the momentum behind the business.

It has landed work with NoBACZ, a spin-out from the University of Cambridge, a new second deal with Nearmedic, and has agreed to run testing for an unnamed Cambridge, Massachusetts biotech.

"We are now continuing to sign additional new virology services contracts with third-party customers,” said Open Orphan chairman Cathal Friel in a statement.

“As such, this is delivering upon one of our key commitments from when we acquired hVIVO earlier this year that, as part of our growth strategy, we were going to expand the range of our service offerings to third party pharmaceutical and biotech companies,“ he added.

NoBACZ is developing an environmentally friendly antimicrobial, antiviral coating that prevents surfaces from being a major source of infection transmission.

It is working with hVIVO at its East London lab to test its products against a range of viruses, including coronaviruses.

It has won a second contract with Nearmedic, this time to support the development of a RegG3 drug as a treatment for COVID-19. This will be followed by the expansion of this product into disease areas such as cystic fibrosis.

Finally, it has inked an agreement to run in vitro testing from its laboratory for the unnamed US biotech company.

Quick facts: Open Orphan PLC

Price: 13.75 GBX

Market: AIM
Market Cap: £91.52 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...



Open Orphan: New deal with top-three pharma company is 'evidence validation...

Proactive Research analyst Emma Ulker says the news this morning that Open Orphan PLC (LON:ORPH) subsidiary hVIVO has signed a £4mln contract with an unnamed top-three global pharma company is evidence that the validation is building as well as recognition amongst larger players in the industry....

2 days, 8 hours ago

2 min read